Paul Hastings LLP, a leading global law firm, represented BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a pharmaceutical company that develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, in connection with its underwritten public offering of 9,775,000 shares of common stock. BioMarin estimated the offering would raise gross proceeds of $911.5 million before costs.
BofA Merrill Lynch acted as representative of the underwriters, J.P. Morgan and Morgan Stanley acted as joint book-running managers for the offering, and Barclays and Deutsche Bank Securities Inc. acted as co-managers for the offering.
Corporate partner Thomas Pollock led the Paul Hastings team, which included partners Leigh Ryan, and Michael Zuppone and associates Aliza Cohen and Christy Chen.
Paul Hastings has also advised BioMarin in a $119.3 offering in March 2014 and a $750 million offering in October 2013.
Source: www.paulhastings.com
